These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30599173)

  • 21. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
    Mailly L; Xiao F; Lupberger J; Wilson GK; Aubert P; Duong FHT; Calabrese D; Leboeuf C; Fofana I; Thumann C; Bandiera S; Lütgehetmann M; Volz T; Davis C; Harris HJ; Mee CJ; Girardi E; Chane-Woon-Ming B; Ericsson M; Fletcher N; Bartenschlager R; Pessaux P; Vercauteren K; Meuleman P; Villa P; Kaderali L; Pfeffer S; Heim MH; Neunlist M; Zeisel MB; Dandri M; McKeating JA; Robinet E; Baumert TF
    Nat Biotechnol; 2015 May; 33(5):549-554. PubMed ID: 25798937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation.
    Colpitts CC; Chung RT; Baumert TF
    ACS Infect Dis; 2017 Sep; 3(9):620-623. PubMed ID: 28812869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.
    Keck ZY; Angus AG; Wang W; Lau P; Wang Y; Gatherer D; Patel AH; Foung SK
    PLoS Pathog; 2014 Aug; 10(8):e1004297. PubMed ID: 25122476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.
    Tarr AW; Lafaye P; Meredith L; Damier-Piolle L; Urbanowicz RA; Meola A; Jestin JL; Brown RJ; McKeating JA; Rey FA; Ball JK; Krey T
    Hepatology; 2013 Sep; 58(3):932-9. PubMed ID: 23553604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing activity and safety of human monoclonal antibodies against hepatitis C virus.
    Abdel Malak CA; Abelhafez TH; Tabll AA; Mashaly MM; El Shenawy R; El-Abd YS; Shaker MH; El-Awady MK
    Hum Antibodies; 2017; 26(3):127-134. PubMed ID: 29036810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
    Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
    J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
    Fauvelle C; Felmlee DJ; Crouchet E; Lee J; Heydmann L; Lefèvre M; Magri A; Hiet MS; Fofana I; Habersetzer F; Foung SK; Milne R; Patel AH; Vercauteren K; Meuleman P; Zeisel MB; Bartenschlager R; Schuster C; Baumert TF
    Gastroenterology; 2016 Jan; 150(1):206-217.e4. PubMed ID: 26404951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    Smith HL; Chung RT; Mantry P; Chapman W; Curry MP; Schiano TD; Boucher E; Cheslock P; Wang Y; Molrine DC
    J Viral Hepat; 2017 Mar; 24(3):197-206. PubMed ID: 28127942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Junctional and somatic hypermutation-induced CX
    Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
    Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
    Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
    Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.
    Eren R; Landstein D; Terkieltaub D; Nussbaum O; Zauberman A; Ben-Porath J; Gopher J; Buchnick R; Kovjazin R; Rosenthal-Galili Z; Aviel S; Ilan E; Shoshany Y; Neville L; Waisman T; Ben-Moshe O; Kischitsky A; Foung SK; Keck ZY; Pappo O; Eid A; Jurim O; Zamir G; Galun E; Dagan S
    J Virol; 2006 Mar; 80(6):2654-64. PubMed ID: 16501075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic options for HCV infection in the monoclonal antibody era.
    Sautto GA; Diotti RA; Clementi M
    New Microbiol; 2012 Oct; 35(4):387-97. PubMed ID: 23109006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
    Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.
    Wasilewski LN; El-Diwany R; Munshaw S; Snider AE; Brady JK; Osburn WO; Ray SC; Bailey JR
    J Virol; 2016 Jan; 90(7):3773-82. PubMed ID: 26819308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
    Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
    J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
    Krieger SE; Zeisel MB; Davis C; Thumann C; Harris HJ; Schnober EK; Mee C; Soulier E; Royer C; Lambotin M; Grunert F; Dao Thi VL; Dreux M; Cosset FL; McKeating JA; Schuster C; Baumert TF
    Hepatology; 2010 Apr; 51(4):1144-57. PubMed ID: 20069648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
    Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
    J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.